Prostatype Genomics AB (FRA:PGO0) Total Liabilities: €2.24 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PGO0 Prostatype Genomics AB FRA:PGO0
23 GF Score
Price €0.01
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Total Liabilities?

Prostatype Genomics AB FRA:PGO0 -1.96% 23 Total Liabilities is €2.24 Mil as of Dec. 2025. GuruFocus rates FRA:PGO0 with a GF Score™ of 23/100. The stock has 5 warning signs investors should review.

Prostatype Genomics AB's Total Liabilities for the quarter that ended in Dec. 2025 was €2.24 Mil.

Prostatype Genomics AB's quarterly Total Liabilities declined from Dec. 2024 (€0.74 Mil) to Jun. 2025 (€0.67 Mil) but then increased from Jun. 2025 (€0.67 Mil) to Dec. 2025 (€2.24 Mil).

Prostatype Genomics AB's annual Total Liabilities declined from Dec. 2023 (€2.20 Mil) to Dec. 2024 (€0.74 Mil) but then increased from Dec. 2024 (€0.74 Mil) to Dec. 2025 (€2.24 Mil).


Prostatype Genomics AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Total Liabilities Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 0.42 0.44 2.20 0.74 2.24

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.20 1.68 0.74 0.67 2.24
FRA:PGO0
23GF Score
Prostatype Genomics AB FRA:PGO0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Prostatype Genomics AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=4.674-2.438
=2.24

Prostatype Genomics AB's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=4.674-2.438
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €2.24 Mil mean?
Prostatype Genomics AB (FRA:PGO0) has a Total Liabilities of €2.24 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Total Liabilities too high?
Prostatype Genomics AB's current Total Liabilities is €2.24 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Total Liabilities compare to TMO and DHR?
Prostatype Genomics AB's Total Liabilities of €2.24 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Total Liabilities is €2.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Prostatype Genomics AB (FRA:PGO0) has a current Total Liabilities of €2.24 Mil. The current Total Liabilities is €2.24 Mil. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Prostatype Genomics AB (FRA:PGO0), the current Total Liabilities is €2.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prostatype Genomics AB Business Description

Other Exchanges PROGEN:Sweden
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score

Get the complete analysis for FRA:PGO0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price